A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma

NCT05606380 | Unknown Phase 1

• 1 other identifier: HLX60-102
• Study Type: interventional
• Target: 11
• Locations: 1 country
• Sites: 1

Brief Summary

This trial is an open, dose escalation phase I clinical study. Subjects can only enter this study after they meet the inclusion and exclusion criteria.Into subjects will accept HLX60 intravenous infusion, every 3 weeks, treatment until lose clinical benefit, toxicity, death, revocation of informed consent.

Conditions

Solid Tumor and Lymphoma

Outcome Measures

Primary Outcomes (2)

• DLT

  The Dose-Limiting Toxicity (DLT) of HLX60 within 3 weeks after the first Administration in patients with Advanced/Metastatic Solid Tumors or Lymphomas

  from day1 to day 21

• MTD

  The Maximum Tolerated Dose (MTD) of HLX60 within 3 weeks after the first Administration in patients with Advanced/Metastatic Solid Tumors or Lymphomas

  from day1 to day 21

Study Arms (1)

HLX60 Group

EXPERIMENTAL

The initial dose of HLX60 is 0.5mg/kg, and 5 dose levels are designed: 2mg/kg, 5mg/kg, 15mg/kg and 25mg/kg (Q3W). Patients will receive the treatment until without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first)

Drug: HLX60

Interventions

HLX60 DRUG

HLX60(anti-GARP Monoclonal Antibody）have 5 dose cohorts: 0.5, 2, 5, 15, 25mg/kg, intravenous infusion, every 3 weeks.

HLX60 Group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged ≥ 18, ≤75 years at the time of signing the ICF;
• Patients with histologically or cytologically confirmed advanced malignant solid tumor or lymphoma, who have failed or cannot receive the standard treatment;
• With at least one evaluable lesion according to RECIST V1.1 (for solid tumors) or the Lugano criteria (for lymphomas);
• Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1 at enrollment;
• Expected survival \> 3 months;
• Have appropriate organ functions;
• The first administration of the investigational product must be: at least 28 days apart from the previous major surgery, medical device treatment, or local radiotherapy; at least 21 days apart from the previous cytotoxic chemotherapy, immunotherapy, and biological agent therapy; at least 14 days apart from the previous hormone therapy and surgical operation; at least 21 days or 5 half-lives apart from the administration of small molecule targeted drugs, whichever is longer; at least 14 days apart from the traditional Chinese medicine for tumor indications;
• For patients with hepatocellular carcinoma, Child-Pugh score has to be A;
• Male and female subjects with child-bearing potential must agree to use at least one highly effective contraception method during the study and within at least 6 months after the last administration of the investigational product.

You may not qualify if:

• Have had other malignant tumors within 3 years before enrollment, except: (a) those with cured cervical carcinoma in situ or non-melanoma skin cancer; (b) those with cured second primary cancer without recurrence within 3 years; (c) those with double primary cancers believed to be able to benefit from this study; (d) those whose metastasis has been clearly excluded from a certain primary tumor source;
• A history of (non-infectious) interstitial lung disease (ILD) requiring steroid use, current ILD, or a suspicion of ILD cannot be ruled out by imaging at screening; Note: Patients with radiation pneumonitis judged to be mild by the investigator can be enrolled.
• The adverse reactions (except alopecia and other adverse reactions determined by the investigator to have no safety risk) of previous anti-tumor therapy have not yet recovered to ≤ grade 1 (CTCAE V5.0);
• Those who are known to have severe anaphylaxis (grade 4 or greater in CTCAE V5.0) to macromolecular protein preparations/monoclonal antibodies or to any component of the investigational product;
• Patients with any of the following unstable or poorly controlled diseases:1)Active systemic infectious diseases requiring intravenous antibiotics within 2 weeks before the first administration of the investigational product;2)Any poorly-controlled cardiovascular and cerebrovascular clinical symptoms or diseases, including but not limited (1) NYHA Class II or greater cardiac failure or left ventricular ejection fraction (LVEF) \<50%;（2）unstable angina pectoris； (3) myocardial infarction and cerebral infarction within 6 months, (4) clinically significant supraventricular or ventricular arrhythmia without clinical intervention or poorly controlled after clinical intervention;3)Other chronic diseases which, in the opinion of the investigator, may compromise the safety of the patient or the integrity of the study;
• Those who have received anti-GARP or anti-GARP/TGF-β antibody therapy;
• Have active autoimmune diseases (including but not limited to the following diseases or syndromes, such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism), except: vitiligo or cured childhood asthma/allergy that does not need any intervention in adulthood, autoimmune mediated hypothyroidism treated with stable dose of thyroid replacement hormone, and type I diabetes treated with stable dose of insulin; those in a stable condition and requiring no systemic immunosuppressant therapy (including corticosteroid hormone) are allowed to be enrolled;
• Have received systemic corticosteroids (prednisone \> 10 mg/d or equivalent dose of similar drug) or other immunosuppressants within 14 days before the first administration; Except: patients treated with topical, ocular, intra-articular, intranasal, and inhaled corticosteroids; those with short term use of corticosteroids for prophylaxis, such as contrast agents;
• Patients in pregnancy \[confirmed by serum beta-human chorionic gonadotropin (ß-HCG) test\] or breastfeeding;
• With a history of immunodeficiency, including human immunodeficiency virus (HIV)-positive or other acquired or congenital immunodeficiencies, or a history of organ transplantation;
• Have active tuberculosis。
• Active HBV, HCV infection or co-infection;
• Have received live vaccines within 28 days prior to the first administration;
• Patients whose medical history or any other evidence suggests that participation in the study may confuse the results, or subjects for whom the investigator believes the study is not in their best interest.

Sponsors & Collaborators

• Shanghai Henlius Biotech: lead

Study Sites (1)

First Affiliated Hospital, College of medicine, Zhejiang University

Hangzhou, China

Location

MeSH Terms

Conditions

Lymphoma

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 1, 2022
• First Posted: November 4, 2022
• Study Start: December 2, 2022
• Primary Completion: August 1, 2024
• Study Completion: February 1, 2025
• Last Updated: April 16, 2024

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)